Alebund AP308 FDA IND Clearance
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Sep 08, 2026
The FDA IND clearance for AP308 is a positive regulatory milestone for Alebund, potentially enhancing its pipeline value and investor sentiment, as reflected in the stock price increase. This development may strengthen Alebund's position in the renal-focused biopharmaceutical market and could attract further investment in its clinical programs.
Alebund Pharmaceuticals announced that the U.S. United States — Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for AP308, a first-in-class engineered recombinant IgA protease for the treatment of IgA nephropathy (IgAN). This clearance allows Alebund to transition AP308 from preclinical research into clinical development, with plans to initiate clinical trials in the near term. AP308 is designed to directly cleave and clear pathogenic IgA and IgA immune complexes deposited in the glomeruli, addressing an unmet medical need in IgAN. Preclinical studies demonstrated significant reduction of IgA deposits and improvement in kidney pathology. Alebund holds global rights to AP308 through a license agreement with Peking University First Hospital. The company's stock rose 4.01% to HKD 27.9 following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard